Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Merck broke ground on a $1B, 470K SF biotech facility last month at the Chestnut Run Innovation & Science Park in Wilmington, ...

As weight loss medications, including Ozempic and WeGovy, have gained popularity across the U.S., they are not without side effects, some serious. According to a May 2024 CNN report, as many as 1 in 8 ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...

Wall Street's major indexes faced declines as President Trump's announcement of upcoming pharmaceutical tariffs rekindled ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

In light of President Donald Trump’s impending pharma tariffs, several big companies have made massive manufacturing ...

U.S. stock index futures fell on Tuesday after President Donald Trump's plans for potential pharma tariffs renewed fears ...

U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

Lilly plans to break ground Tuesday afternoon on its $4.5 billion Lilly Medicine Foundry in Lebanon. Lilly Chair and CEO Dave ...

Ford Motor was the latest to suspend its annual outlook on Monday, joining a host of companies that shelved their forecasts ...